Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Bought by California State Teachers Retirement System

California State Teachers Retirement System boosted its holdings in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) by 13.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 22,178 shares of the company’s stock after acquiring an additional 2,569 shares during the quarter. California State Teachers Retirement System’s holdings in Apogee Therapeutics were worth $1,005,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Driehaus Capital Management LLC increased its stake in Apogee Therapeutics by 2.8% during the fourth quarter. Driehaus Capital Management LLC now owns 2,605,310 shares of the company’s stock worth $118,021,000 after acquiring an additional 71,703 shares during the last quarter. Alliancebernstein L.P. increased its stake in Apogee Therapeutics by 13.5% during the fourth quarter. Alliancebernstein L.P. now owns 1,355,185 shares of the company’s stock worth $61,390,000 after acquiring an additional 160,822 shares during the last quarter. Paradigm Biocapital Advisors LP increased its stake in Apogee Therapeutics by 82.9% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 1,283,766 shares of the company’s stock worth $58,155,000 after acquiring an additional 581,949 shares during the last quarter. Janus Henderson Group PLC increased its stake in Apogee Therapeutics by 141.7% during the fourth quarter. Janus Henderson Group PLC now owns 1,135,100 shares of the company’s stock worth $51,455,000 after acquiring an additional 665,543 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in Apogee Therapeutics by 38.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,052,595 shares of the company’s stock worth $47,683,000 after acquiring an additional 294,514 shares during the last quarter. Institutional investors and hedge funds own 79.04% of the company’s stock.

Analyst Upgrades and Downgrades

APGE has been the subject of several recent analyst reports. Wedbush reissued an “outperform” rating and set a $90.00 target price on shares of Apogee Therapeutics in a research note on Tuesday, March 11th. Citigroup started coverage on Apogee Therapeutics in a research note on Thursday, March 13th. They issued a “buy” rating and a $95.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $94.60.

Insider Activity at Apogee Therapeutics

In related news, insider Carl Dambkowski sold 2,725 shares of Apogee Therapeutics stock in a transaction on Wednesday, June 4th. The stock was sold at an average price of $36.96, for a total value of $100,716.00. Following the completion of the transaction, the insider now directly owns 241,723 shares in the company, valued at approximately $8,934,082.08. This trade represents a 1.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last three months, insiders sold 9,310 shares of company stock worth $337,944. Company insiders own 42.77% of the company’s stock.

Apogee Therapeutics Trading Up 4.7%

Shares of NASDAQ APGE opened at $42.02 on Wednesday. Apogee Therapeutics, Inc. has a twelve month low of $26.20 and a twelve month high of $63.50. The stock has a fifty day simple moving average of $36.58 and a 200-day simple moving average of $39.47. The stock has a market capitalization of $1.93 billion, a PE ratio of -17.36 and a beta of 1.38.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.95) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.19) by $0.24. On average, equities analysts predict that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current year.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.